Neoadjuvant Therapy of Breast Cancer – what role?
Abstract
.Downloads
Download data is not yet available.
References
Registo Oncológico Nacional de todos os tumores malignos na população residente em Portugal em 2006, ROR SUL, 2006.
Sorlie T, Perou CM, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2007;98: 70869-70874
Berry D.A., Cronin K.A., Plevritis S.K., et al : Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. N Engl J Med 2005; 353:7784-7792.
Hortobagyi GN, Blumenschein GR, Spanos W, et al: Multimodal treatment of locoregionally advanced breast cancer. Cancer 7983;57:763-768.
Hutcheon AW, Heys SD, Sarkar TK, et al: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res. Treat. 2003;82(supplement 7):p. S6.
Rastogi R, Anderson SJ, Bear HD: Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-78 and B-27. J Clin Oncol. 2008; 26: 778-85.
Van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 70902. J Clin Oncol. 2007; 79: 4224-37.
Mieog JS, van der Hage JA, van de Velde CJ : Preoperative chemotherapy for women with operable breast cancer. Cochrane Database of Systematic Reviews, no2, 2007; CD005002.
Gianni L, Eiermann W, Semiglazov V, et al : Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neo- adjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2070; 375:377-84.
Tatiana M. Prowell, and Richard Pazdur: Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer. N Engl J Med; 366: 2438-2447.
Mauri D, Pavlidis N, Ioannidis JP : Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97:788-94.
Cuppone F, Bria E, Carlini P, et al: Taxanes as primary chemotherapy for early breast cancer : meta-analysis of randomized trials. Cancer. 2008; 773:238-46.
Smith IE, A’Hern RP, Coombes GA, et al: A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology. 2004;75:757-758.
Chua S, Smith IE, A’Hern RP, et al: Neoadjuvant vinorelbine/epirubicin (VE) versus standard Adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trail (TOPIC 2). Annals of Oncology. 2005;76:7435-7447.
Earl HM, Vallier A, Hiller L, et al: Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel+/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009;27(supplement 75, abstract 522).
Von Minckwitz G, Rezai M, Loibl S, et al: Capecitabine in addition to anthracycline- and taxane- based neoadjuvant treatment in patients with primary breast cancer : phase III GeparQuattro Study. J Clin Oncol. 2070;28:2075-2023.
Mazouni C, Peintinger F, Wan-Kau S, et al : Residual ducatl carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650-2655.
Von Minckwitz G, Untch M, Blohmer JU, et al : Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2072; 30:7796-7804.
Carey LA, Dees EC, Sawyer L, et al: The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res. 2007 ; 73:2329-34.
Von Minckwitz G, Blohmer JU, Costa S, et al : Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients- results of the gepartrio trial. Cancer Res 2077; 77(24, abstract S3-2).
Huober J, Hanusch C, Fasching PA, et al: Neoadjuvant chemotherapy of paclitaxel with or without Rad007: results of the non-responder part of the GEPARQUINTO study. Cancer Res. 2077;77(24, abstract 3-6).
Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 7 year after adjuvant chemotherapy in patients with HER2-positive
early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2077; 72:236-44.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:7673-7684.
Buzdar AU, Ibrahim N, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemo- therapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23:3676-3685.
Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. The Lancet. 2072;379:633-40
Gianni L, Pienkowski T, Im Y-H, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflamatory, or early HER 2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology. 2072;73:25-32.
Ismael G, Hegg R, Muehlbauer S, et al: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology 2072;73:869 - 878.
Pivot X, Gligorov J, Müller V, et al: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-
positive early breast cancer (PrefHer): an open-label randomised study. The Lancet Oncology, 2073; 74:962 - 970.
Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of ki67 expression after short-term presurgical endocrine therapy for primary breast
cancer. J National Cancer Inst. 2007;99:767-770.
Sorlie T, Perou CM, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2007;98: 70869-70874
Berry D.A., Cronin K.A., Plevritis S.K., et al : Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. N Engl J Med 2005; 353:7784-7792.
Hortobagyi GN, Blumenschein GR, Spanos W, et al: Multimodal treatment of locoregionally advanced breast cancer. Cancer 7983;57:763-768.
Hutcheon AW, Heys SD, Sarkar TK, et al: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res. Treat. 2003;82(supplement 7):p. S6.
Rastogi R, Anderson SJ, Bear HD: Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-78 and B-27. J Clin Oncol. 2008; 26: 778-85.
Van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 70902. J Clin Oncol. 2007; 79: 4224-37.
Mieog JS, van der Hage JA, van de Velde CJ : Preoperative chemotherapy for women with operable breast cancer. Cochrane Database of Systematic Reviews, no2, 2007; CD005002.
Gianni L, Eiermann W, Semiglazov V, et al : Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neo- adjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2070; 375:377-84.
Tatiana M. Prowell, and Richard Pazdur: Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer. N Engl J Med; 366: 2438-2447.
Mauri D, Pavlidis N, Ioannidis JP : Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97:788-94.
Cuppone F, Bria E, Carlini P, et al: Taxanes as primary chemotherapy for early breast cancer : meta-analysis of randomized trials. Cancer. 2008; 773:238-46.
Smith IE, A’Hern RP, Coombes GA, et al: A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology. 2004;75:757-758.
Chua S, Smith IE, A’Hern RP, et al: Neoadjuvant vinorelbine/epirubicin (VE) versus standard Adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trail (TOPIC 2). Annals of Oncology. 2005;76:7435-7447.
Earl HM, Vallier A, Hiller L, et al: Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel+/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009;27(supplement 75, abstract 522).
Von Minckwitz G, Rezai M, Loibl S, et al: Capecitabine in addition to anthracycline- and taxane- based neoadjuvant treatment in patients with primary breast cancer : phase III GeparQuattro Study. J Clin Oncol. 2070;28:2075-2023.
Mazouni C, Peintinger F, Wan-Kau S, et al : Residual ducatl carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650-2655.
Von Minckwitz G, Untch M, Blohmer JU, et al : Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2072; 30:7796-7804.
Carey LA, Dees EC, Sawyer L, et al: The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res. 2007 ; 73:2329-34.
Von Minckwitz G, Blohmer JU, Costa S, et al : Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients- results of the gepartrio trial. Cancer Res 2077; 77(24, abstract S3-2).
Huober J, Hanusch C, Fasching PA, et al: Neoadjuvant chemotherapy of paclitaxel with or without Rad007: results of the non-responder part of the GEPARQUINTO study. Cancer Res. 2077;77(24, abstract 3-6).
Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 7 year after adjuvant chemotherapy in patients with HER2-positive
early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2077; 72:236-44.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:7673-7684.
Buzdar AU, Ibrahim N, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemo- therapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23:3676-3685.
Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. The Lancet. 2072;379:633-40
Gianni L, Pienkowski T, Im Y-H, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflamatory, or early HER 2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology. 2072;73:25-32.
Ismael G, Hegg R, Muehlbauer S, et al: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology 2072;73:869 - 878.
Pivot X, Gligorov J, Müller V, et al: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-
positive early breast cancer (PrefHer): an open-label randomised study. The Lancet Oncology, 2073; 74:962 - 970.
Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of ki67 expression after short-term presurgical endocrine therapy for primary breast
cancer. J National Cancer Inst. 2007;99:767-770.
Published
2014-01-31
How to Cite
NAVE, Mónica; PASSOS COELHO, J. L..
Neoadjuvant Therapy of Breast Cancer – what role?.
Revista Portuguesa de Cirurgia, [S.l.], n. 27, p. 71-76, jan. 2014.
ISSN 2183-1165.
Available at: <https://revista.spcir.com/index.php/spcir/article/view/334>. Date accessed: 23 apr. 2024.
Section
Special Notebook
